司美格鲁肽治疗非增生型糖尿病视网膜病变患者的临床疗效  

Clinical efficacy of semaglutide in patients with non-proliferative diabetic retinopathy

作　　者：黄海 孙琴 唐义权 Huang Hai;Sun Qin;Tang Yi-quan(Department of Ophthalmology,Hai’an People’s Hospital,Hai’an 226600,China)

机构地区：[1]海安市人民医院眼科,海安226600

出　　处：《中国药物应用与监测》2024年第6期817-820,共4页Chinese Journal of Drug Application and Monitoring

基　　金：南通市市级科技计划项目(MSZ20178)

摘　　要：目的探讨对非增生型糖尿病视网膜病变(NPDR)患者应用司美格鲁肽联合羟苯磺酸钙治疗的效果。方法选取海安市人民医院2021年7月至2023年3月收治的NPDR患者共86例,经随机数字表法分为两组,对照组(43例)给予羟苯磺酸钙,观察组(43例)在对照组的基础上加用司美格鲁肽治疗。比较两组临床疗效、治疗前后空腹血糖(FBG)、糖化血红蛋白(HbAlc)、最佳矫正视力(BCVA)、黄斑区视网膜神经上皮层厚度(CRT)、视野灰度值、血管瘤体积、出血斑面积变化。结果观察组治疗有效率90.69%(39/43)高于对照组72.09%(31/43)(χ^(2)=4.917,P<0.05)。治疗后观察组FBG、HbAlc[(7.12±1.69)mmol·L^(-1)、(6.22±1.07)%]低于对照组[(8.34±1.73)mmol·L^(-1)、(7.31±1.28)%](t=3.307、4.284,均P<0.05)。治疗后观察组的BCVA(0.62±0.12)高于对照组(0.51±0.11),CRT、视野灰度值、血管瘤体积、出血斑面积[(308.19±23.07)μm、(1.47±0.46)%、(11.19±2.07)μm^(3)、(1.24±0.20)mm^(2)]低于对照组[(334.31±22.48)μm、(2.28±0.73)%、(14.31±2.48)μm^(3)、(1.78±0.26)mm^(2)](t=4.431、5.317、6.155、6.333、10.749,均P<0.05)。两组不良反应发生率差异无统计学意义[11.62%(5/43)vs 4.65%(2/43),χ^(2)=0.622,P>0.05]。结论司美格鲁肽联合羟苯磺酸钙治疗NPDR患者疗效显著,可有效增强血糖控制效果、促进眼底病变的修复,控制病变的进展,改善患者的视觉功能,且具有良好的安全性。Objective To investigate the efficacy of semaglutide combined with calcium dobesilate for the treatment of patients with non-proliferative diabetic retinopathy(NPDR).Methods A total of 86 NPDR patients admitted to Hai’an People’s Hospital from July 2021 to March 2023 were divided into two groups using the random number table method.The patients in the control group(n=43)were given calcium dobesilate while those in the observation group(n=43)were given semaglutide based on the regimen in the control group.The clinical efficacy,fasting blood glucose(FBG),glycosylated hemoglobin(HbA1c),best corrected visual acuity(BCVA),central retinal thickness(CRT),visual field gray value,hemangioma volume and bleeding spot area before and after treatment were compared between the two groups.Results The effective rate in the observation group was 90.69%(39/43),which was higher than that of 72.09%in the control(31/43)(χ^(2)=4.917,P<0.05).After treatment,FBG and HbAlc were significantly lower in the observation group than in the control((7.12±1.69)mmol·L^(-1)vs(8.34±1.73)mmol·L^(-1),(6.22±1.07)%vs(7.31±1.28)%)(t=3.307,4.284,P<0.05).BCVA was higher in the observation group than in the control((0.62±0.12)vs(0.51±0.11)).The levels of CRT,visual field gray value,hemangioma volume,and bleeding spot area were(308.19±23.07)μm,(1.47±0.46)%,(11.19±2.07)μm^(3),(1.24±0.20)mm^(2)in the observation group,which were remarkably lower than those of(334.31±22.48)μm,(2.28±0.73)%,(14.31±2.48)μm^(3),(1.78±0.26)mm^(2)in the control(t=4.431,5.317,6.155,6.333,10.749,P<0.05).There was no significant difference in the adverse reaction rate between the two groups(11.62%(5/43)vs 4.65%(2/43),χ^(2)=0.622,P<0.05).Conclusion Semaglutide combined with calcium dobesilate has significant efficacy in the treatment of patients with NPDR.It can effectively enhance blood sugar control,promote the repair of fundus lesions,control the progression of lesions,improve the visual function of patients,and has good safety.

关 键 词：司美格鲁肽 羟苯磺酸钙 非增生型糖尿病视网膜病变 临床疗效 胰高血糖素样肽-1受体激动剂 

分 类 号：R774.1[医药卫生—眼科] R587.2[医药卫生—临床医学]